AGE1 | Activity | F4AGE1 Activity
Every public signal F4 has attached to this firm, with sources and cross-entity links.
Essay
Published an essay on intervening in the aging immune system to reshape cancer prevention.
How the Aging Immune System Rewrites Cancer Prevention
Portfolio company Aerska strengthened leadership and board with key appointments to advance RNA medicines for the brain.
3 essays· FEB 2026Show all
Essay
Published a guide on the five key decisions between a validated target and a clinical program.
Founder's Playbook: From Target to Development Strategy
Essay
Published a framework for enabling technologies in longevity biotech and solicited proposals for addressing five key frontiers in the field.
Five Unconquered Frontiers for Longevity biotech: Our 2026 Call for Proposals
Essay
Published a framework for target validation in drug development before significant capital commitment.
The Cheapest Insurance in Drug Development
Investment
Co-led Aerska's $39M Series A alongside EQT Dementia Fund to deliver RNA medicines to the brain.
Aerska
Investment
Co-led Aerska's $39M Series A for brain shuttle technology to deliver RNA medicines to the brain for neurological diseases.
Aerska
Essay
Published a strategic framework for context-preserving target discovery in biotech.
Hunting Targets in Their Native Environment
Investment
Led Loyal's $100M Series C to advance the first canine longevity drug.
Loyalfordogs